On September 7, 2023, Luye Life Sciences Group, in collaboration with the Ministry of Higher Education, Science, and Innovation of Uzbekistan, celebrated a signing ceremony in Tashkent for their joint initiative – establishing an Innovative Vaccine and Biotechnology Center in Uzbekistan. The event took place during the visit of a delegation from China's Shandong Province, led by Lin Wu, the Provincial Party Secretary. This endeavor signals the commencement of the Group's business expansion into Central Asia, a move expected to solidify its global presence.
The ceremony was graced by the presence of Lin Wu, Zhang Haibo (Member and Secretary-General of the Shandong Provincial Party Standing Committee), and Yu Jun (Chinese Ambassador to Uzbekistan). Liu Dianbo, Board Chairman of Luye Life Sciences Group, and Shahlo Turdikulova, Deputy Minister of Higher Education, Science, and Innovation of Uzbekistan, attended the ceremony as representatives of their respective signing parties and engaged in discussions aimed at elevating technological cooperation to new heights.
According to the agreement, both parties will commit their respective strengths and resources to jointly build as equal partners the Innovative Vaccine and Biotechnology Center in Uzbekistan. Rooted in principles of mutual benefit and win-win collaboration, this project will catalyze comprehensive cooperation in the domains of innovative pharmaceuticals and vaccines between China, Uzbekistan, and the broader Central Asian region, fostering innovation in the pharmaceutical sector of both nations.
The Group’s products and services are currently available in more than 80 countries and regions. Central Asia, positioned as a pivotal nexus connecting Asia and Europe, holds immense development potential. Uzbekistan, nestled at the heart of Central Asia, boasts unique geographical advantages. The journey towards this landmark initiative commenced on September 13, 2022, when the Group embarked on discussions with the Uzbekistan Ministry of Innovative Development (now the Ministry of Higher Education, Science, and Innovation), culminating in the signing of a strategic cooperation memorandum. After a year of research and preparation, the two sides successfully launched the Innovative Vaccine and Biotechnology Center project. In June this year, Xuezhikang, an exclusive lipid-lowering drug of the Group with international recognition, was approved for marketing in Uzbekistan, adding another chapter to the success story of Chinese medicines making a mark on the global stage. Recently, the Group set up a subsidiary in Uzbekistan and formed a local commercial team dedicated to driving its business in Central Asia.
The Group is committed to the meticulous execution of the Uzbekistan project through active collaboration with all stakeholders. Underpinned by the Group’s cutting-edge technologies, this initiative aims to accelerate innovation in medicines throughout Central Asia. The Group will continue to attract more nations to partake in this cooperative effort designed to foster regional economic growth. Together with all partners, the Group aspires to promote the "Health Silk Road" initiative in Central Asia for the well-being of the region’s population.
TOP